Niu Kunwei, Qu Shibin, Yang Long, Zhang Hong, Yuan Juzheng, Fan Hanlu, Li Xiao, Tao Kaishan
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, 127 Changle Road, Xi'an, Shaanxi 710032, China.
Surg Open Sci. 2023 Mar 2;12:35-42. doi: 10.1016/j.sopen.2023.03.003. eCollection 2023 Mar.
The effects of isoform-specific histone deacetylase inhibitors (HDACIs) and the non-selective HDACI on sepsis have been profoundly reported. However, the best HDAC classes have not been fully evaluated. Therefore, this study aimed to determine which HDACIs are responsible for survival and beneficial for organ injury.
Experiment I, SD rats were subjected to cecal ligation and puncture and randomly assigned to the no treatment, dimethyl sulfoxide (DMSO) only, MS-275, LMK-235, tubastatinA (TubA), trichostatin-A (TSA), and sirtinol groups (n = 5). Survival was monitored for 48 h. Experiment II, the animals were monitored for 12 h, then, blood and tissues sample were collected. Interleukin (IL)-6, IL-1β, tumour necrosis factor (TNF)-α, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK) and lactate dehydrogenase (LDH) expressions were evaluated using ELISA. Liver, heart and lung tissues were analysed via hematoxylin and eosin staining. Liver and heart tissue lysates were analysed for acetylated histones H3, H4, a-tubulin and nuclear factor kappa B (NF-κB), IL-6, IL-1β, and TNF-α using western blotting. Splenocytes were examined via flow cytometry to analyse the immune cell population.
MS-275, TubA and TSA treatments significantly prolonged survival. MS-275, LMK-235, TubA and TSA significantly reduced the histopathological scores and AST, ALT, CK, LDH, IL-6, IL-1β and TNF-α levels, significantly increased acetylated of NF-κB and changed the immune cell proportion.
Our results indicated that HDACI classes I and IIb and non-selective HDACI can significantly prolong survival. Moreover, non-selective and isoform-specific class I and IIa/IIb HDACIs can attenuate inflammation and organ injury.
关于亚型特异性组蛋白去乙酰化酶抑制剂(HDACIs)和非选择性组蛋白去乙酰化酶抑制剂(HDACI)对脓毒症的影响已有大量报道。然而,最佳的HDAC类别尚未得到充分评估。因此,本研究旨在确定哪些HDACIs对生存有益且对器官损伤有保护作用。
实验I,将SD大鼠行盲肠结扎和穿刺术,随机分为未治疗组、仅用二甲基亚砜(DMSO)组、MS-275组、LMK-235组、tubastatinA(TubA)组、曲古抑菌素A(TSA)组和sirtinol组(n = 5)。监测48小时的生存率。实验II,对动物监测12小时,然后采集血液和组织样本。使用酶联免疫吸附测定(ELISA)评估白细胞介素(IL)-6、IL-1β、肿瘤坏死因子(TNF)-α、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、肌酸激酶(CK)和乳酸脱氢酶(LDH)的表达。通过苏木精和伊红染色分析肝、心、肺组织。使用蛋白质印迹法分析肝和心脏组织裂解物中的乙酰化组蛋白H3、H4、α-微管蛋白和核因子κB(NF-κB)、IL-6、IL-1β和TNF-α。通过流式细胞术检查脾细胞以分析免疫细胞群体。
MS-275、TubA和TSA治疗显著延长了生存期。MS-275、LMK-235、TubA和TSA显著降低了组织病理学评分以及AST、ALT、CK、LDH、IL-6、IL-1β和TNF-α水平,显著增加了NF-κB的乙酰化水平并改变了免疫细胞比例。
我们的结果表明,I类和IIb类HDACI以及非选择性HDACI可显著延长生存期。此外,非选择性和亚型特异性的I类以及IIa/IIb类HDACIs可减轻炎症和器官损伤。